Neurocognitive Deficit

2

Review clinical trials related to Neurocognitive Deficit. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets

Brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. With improvements in systemic therapy that prolong survival but have limited central nervous system penetration, patients with brain metastases are at increasing risk of developing and experiencing long-term side effects from treatment of brain metastases. The overarching goal of this study is to better understand the determinants of RT-associated changes in white and gray matter function and associated neurocognitive decline.

Participants needed: 20
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: UNC Lineberger Comprehensive Cancer CenterUpdated: Aug 14, 2026Locations: 1
Eligibility criteria

Histologic diagnosis of cancer [+6]

Previous radiation to the brain or head [+4]

Status: Recruiting

The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units?

Here, the investigators propose to study host responses to reduced microbiome complexity driven by treatment with broad spectrum antibiotics in patients with severe infections or sepsis. The proposal aims to combine holistic approaches with emerging experimental technologies to investigate the complex interactions between the gut microbiota and its host and assess the impact of specific bacterial communities on longevity and stress responses. A strong focus of this study will also be placed on microbiome dysbiosis and secondary impacts on short- and long-term brain dysfunction using clinical, laboratory and imaging procedures.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Jena University HospitalUpdated: Dec 30, 2024Locations: 1
Eligibility criteria

Age ≥ 18 years [+4]

Inflammatory bowel disease [+10]